

# GREEN IMPACT

우수한 내약성과 뛰어난 효과<sup>1</sup>



## Green Impact, Toviaz

- **POWERFUL** 디트루시톨 SR 4mg 대비 토비아즈 8mg의 우월한 UUI 개선효과<sup>2</sup>
- **OPTIMIZED** 토비아즈 4/8mg으로 환자의 개별적인 필요에 따른 맞춤 치료 가능<sup>3,4</sup>
- **PROVEN** 토비아즈 4/8mg의 UUI 및 주요 OAB 증상 개선효과<sup>4</sup>
- **LONG-TERM TOLERABILITY** 3년간의 공개라벨 연장 연구에서도 보여준 토비아즈의 우수한 내약성과 안전성 프로파일<sup>5</sup>
- **PREDICTABLE** 토비아즈 4/8mg의 일관되고 예측 가능한 약물 동력학 프로파일<sup>6</sup>

4mg 으로 시작하세요!

**References** 1. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. 2007;52:1204-1212. 2. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105:58-66. 3. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU Int. 2011 Feb;107(4):603-11. doi: 10.1111/j.1464-410X.2010.09587.x. 4. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008 May;71:839-843. 5. P.E.V. Kerrebroeck, J. Heesakkers, S. Berriman, L. Padmanabhan Aiyer, M. Carlsson and Z. Guan. Long-term safety, tolerability and efficacy of fesoterodine treatment in subject with overactive bladder symptoms. Int J Clin Pract. 2010; 64:201-204 6. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J of Clin Pharmacol Ther. 2008; 45 (11):556-563.

KRFES1406.01